Cargando…

Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape

BACKGROUND: The epidermal growth factor receptor (EGFR) is a therapeutic target for non-small cell lung cancer (NSCLC), but knowledge on gene mutations that contribute to NSCLC development and persistence is lacking. In this study, we investigated genetic variations in EGFR and their association wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Wei, Mao, Wenjun, Chen, Ruo, Lu, Rongguo, Liu, Feng, He, Yijun, Wang, Shengfei, Li, Xiaomin, Zheng, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880631/ https://www.ncbi.nlm.nih.gov/pubmed/31746315 http://dx.doi.org/10.12659/MSM.920042

Ejemplares similares

lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2
por: Mao, Wenjun, et al.
Publicado: (2022)

Erratum to “lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2”
por: Mao, Wenjun, et al.
Publicado: (2022)

Germline mutation analyses of malignant ground glass opacity nodules in non-smoking lung adenocarcinoma patients
por: Mao, Wenjun, et al.
Publicado: (2021)

Recurrent lung adenocarcinoma benefits from microwave ablation following multidisciplinary treatments: A case with long-term survival
por: Jiang, Guanyu, et al.
Publicado: (2023)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
por: Bacchi, Carlos E., et al.
Publicado: (2012)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non–small cell lung cancer
por: Mao, Wenjun, et al.
Publicado: (2022)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
por: Martin, Petra, et al.
Publicado: (2016)

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
por: Majem, Margarita, et al.
Publicado: (2022)

Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer
por: Zhang, Liwen, et al.
Publicado: (2017)

Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis
por: Zhang, Zhixuan, et al.
Publicado: (2014)

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
por: Usui, Kazuhiro, et al.
Publicado: (2011)

Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics
por: Mei, Jie, et al.
Publicado: (2022)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
por: Sutani, A, et al.
Publicado: (2006)

Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
por: Lu, Chao-Wen, et al.
Publicado: (2023)

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
por: Jiang, Shirley Xue, et al.
Publicado: (2019)

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
por: Harrison, Peter T., et al.
Publicado: (2020)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung
por: Somaiah, Neeta, et al.
Publicado: (2014)

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
por: Huang, Shu-Mei, et al.
Publicado: (2017)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
por: Lim, Malcolm, et al.
Publicado: (2022)

Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
por: Liu, Lihui, et al.
Publicado: (2021)

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
por: Peng, Xinyi, et al.
Publicado: (2023)

Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer
por: Na, Im Il, et al.
Publicado: (2011)

Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
por: Bhatt, Vijaya Raj, et al.
Publicado: (2016)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

Rad51 in regulating the radiosensitivity of non‐small cell lung cancer with different epidermal growth factor receptor mutation status
por: Zhong, Xing, et al.
Publicado: (2015)

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
por: Ma, Lin, et al.
Publicado: (2021)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma
por: Li, Bo, et al.
Publicado: (2021)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
por: Hsu, Chia-Hung, et al.
Publicado: (2016)

Epidermal growth factor receptor mutated oligometastatic adeno-squamous lung cancer transformation to small cell lung cancer
por: O’Leary, Connor G, et al.
Publicado: (2018)

Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy
por: Zhou, Jianmei, et al.
Publicado: (2023)

Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction
por: Xu, Qing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_klokegi83tcv90bivk8lr2c2j2